201. Oral Treatment with Iododiflunisal Delays Hippocampal Amyloid-β Formation in a Transgenic Mouse Model of Alzheimer’s Disease: A Longitudinal in vivo Molecular Imaging Study1
- Author
-
Jesús Jiménez-Barbero, Edurne Mujica, Luka Rejc, Vanessa Gómez-Vallejo, Ellen Y. Cotrina, Zuriñe Baz, Jordi Quintana, Isabel Cardoso, Xabier Rios, Tiago Gião, Unai Cossío, Gemma Arsequell, and Jordi Llop
- Subjects
0301 basic medicine ,Genetically modified mouse ,medicine.medical_specialty ,Mice, 129 Strain ,Administration, Oral ,Mice, Transgenic ,Hippocampal formation ,Hippocampus ,Amyloid beta-Protein Precursor ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Alzheimer Disease ,In vivo ,Positron Emission Tomography Computed Tomography ,Internal medicine ,medicine ,Animals ,Longitudinal Studies ,Florbetaben ,Mice, Inbred C3H ,biology ,Tolcapone ,business.industry ,General Neuroscience ,General Medicine ,Diflunisal ,Molecular Imaging ,Psychiatry and Mental health ,Clinical Psychology ,Transthyretin ,030104 developmental biology ,Endocrinology ,Toxicity ,biology.protein ,Immunohistochemistry ,Female ,Geriatrics and Gerontology ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Background: Transthyretin (TTR) is a tetrameric, amyloid-β (Aβ)-binding protein, which reduces Aβ toxicity. The TTR/Aβ interaction can be enhanced by a series of small molecules that stabilize its tetrameric form. Hence, TTR stabilizers might act as disease-modifying drugs in Alzheimer’s disease. Objective: We monitored the therapeutic efficacy of two TTR stabilizers, iododiflunisal (IDIF), which acts as small-molecule chaperone of the TTR/Aβ interaction, and tolcapone, which does not behave as a small-molecule chaperone, in an animal model of Alzheimer’s disease using positron emission tomography (PET). Methods: Female mice (AβPPswe/PS1A246E/TTR+/–) were divided into 3 groups (n = 7 per group): IDIF-treated, tolcapone-treated, and non-treated. The oral treatment (100 mg/Kg/day) was started at 5 months of age. Treatment efficacy assessment was based on changes in longitudinal deposition of Aβ in the hippocampus (HIP) and the cortex (CTX) and determined using PET-[18F]florbetaben. Immunohistochemical analysis was performed at age = 14 months. Results: Standard uptake values relative to the cerebellum (SUVr) of [18F]florbetaben in CTX and HIP of non-treated animals progressively increased from age = 5 to 11 months and stabilized afterwards. In contrast, [18F]florbetaben uptake in HIP of IDIF-treated animals remained constant between ages = 5 and 11 months and significantly increased at 14 months. In the tolcapone-treated group, SUVr progressively increased with time, but at lower rate than in the non-treated group. No significant treatment effect was observed in CTX. Results from immunohistochemistry matched the in vivo data at age = 14 months. Conclusion: Our work provides encouraging preliminary results on the ability of small-molecule chaperones to ameliorate Aβ deposition in certain brain regions.
- Published
- 2020